drugset / Trial / NCT03054766

Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

NCT03054766

Completed 80 enrolled Beijing Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the efficacy of laser photocoagulation combined with ranibizumab intravitreal injection in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in long term.

Timeline

Start
2017-02-14
Primary completion
2018-02-01
Completion
2019-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal